The mean duration of exposure to the study drug was 690 days in the lixisenatide group and 712 days in the placebo group
Safety, side effects, and clinical oversight The FDA-labeled side-effect profile for GLP-1 receptor agonists and the GIP/GLP-1 dual agonist tirzepatide is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common
The FDA classified Epitalon as a Category 2 bulk drug substance under Section 503A guidance in September 2023, confirmed in September 2024
a number of other patents and patent applications contain prophetic disclosures of combination therapy where one agent is a melanocortin receptor agonist and a second agent is a PDE-5 inhibitor
My confidence has improved 100%
Relationship between semen quality and the seminal plasma components carnitine, alpha-glucosidase, fructose, citrate and granulocyte elastase in infertile men compared with a normal population